Data demonstrate potent suppression of MAPK signaling and viability in KRAS mutant cell lines, as well as anti-tumor activity across multiple KRASG12D and KRASG12V cell-derived xenograft (CDX) modelsBBO-11818’s selectivity for KRAS demonstrated by its >1000-fold lower potency against NRAS, HRAS, and BRAF-mutant cell linesEfficacy of the combination with BBOT’s RAS:PI3K⍺ breaker, BBO-10203, is driven by a robust decrease in tumor cell proliferation and increase in apoptosis; combination benefit also observed ...